Krystexxa

Krystexxa Uses, Dosage, Side Effects, Food Interaction and all others data.

Krystexxa is a recombinant porcine-like uricase drug indicated for the treatment of severe, treatment-refractory, chronic gout. Similarly to rasburicase, pegloticase metabolises the conversion of uric acid to allantoin. This reduces the risk of precipitate formation and development of gout, since allantoin is five to ten times more soluble than uric acid. Krystexxa is a pegylated form of uricase which offers an extended half-life of ten-12 days compared to rasburicase's 8 hours. It also offers reduced immunogenicity due to the bulky PEG group. The longer haf-life allows for less frequent dosing at once every 2-4 weeks making pegloticase more convenient for chronic use.

Krystexxa
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Krystexxa
Availability	Prescription only
Generic	Pegloticase
Pegloticase Other Names	Pegloticase, Puricase
Related Drugs	allopurinol, febuxostat, Zyloprim, probenecid, Uloric, Krystexxa
Weight	8mg/ml,
Type	Intravenous solution
Formula	C₁₅₄₉H₂₄₃₀N₄₀₈O₄₄₈S₈
Weight	34192.8533 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States, Netherlands,
Last Updated:	September 19, 2023 at 7:00 am

Uses

Krystexxa is a recombinant uricase used for the treatment of chronic gout in adult patients refractory to conventional therapy.

For the treatment of chronic gout in adult patients refractory to conventional therapy.

Krystexxa is also used to associated treatment for these conditions: Chronic, refractory Gout

How Krystexxa works

Krystexxa is a recombinant uricase that catalyzes the metabolism of uric acid to allantoin.

Toxicity

Conditions that should be monitored for when starting treatment with pegloticase include anaphylaxis, infusion reactions, an increase in gout flares, and/or an exacerbation of pre-existing congestive heart failure.

Food Interaction

No interactions found.

Krystexxa Disease Interaction

Major: G6PD deficiencyModerate: congestive heart failure

Elimination Route

Approximately 24 hours following the first dose, mean plasma uric acid levels were 0.7 mg/dL. The duration of suppression of plasma uric acid appeared to be positively associated with pegloticase dose. Sustained decrease in plasma uric acid below the solubility concentration of 6 mg/dL for more than 300 hours was observed with doses of 8 mg and 12 mg.